Proteinuria is associated with a higher risk of sudden cardiac arrest in young adults, especially with chronic kidney disease ...

A new study published in the journal of BMC Nephrology showed that in individuals with primary membranous nephropathy (PMN), ...

Although SCA was rare in a Korean population-based study -- occurring in 0.08% of over 6.8 million adults under age 40 -- it was more likely in those whose routine lab results flagged proteinuria ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Sudden cardiac arrest survival rates are only around 10%, but new research spotted a test that may flag warning in young adulthood.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS ...

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...

A new study led by Dr. Hilla Chen from the Koret School of Veterinary Medicine at Hebrew University, recently published in ...

Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease ...